SCHEMBL20508211

SCHEMBL20508211

Cc1cc(-c2ncc(CNC(=O)c3csc(-c4ccccc4)n3)cc2C)ccn1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ WNT3A P56704 3/20 0.52
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ TLR7 Q9NYK1 1/20 0.47
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ HPGDS O60760 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18974100 0.85 RAB9A (0.58) WNT3ANPC1RAB9AHPGD
SCHEMBL20507904 0.84 WNT3A (0.55) WNT3A
SCHEMBL18974328 0.83 WNT3A (0.52) WNT3A
SCHEMBL20507984 0.83 WNT3A (0.52) WNT3ATLR7
SCHEMBL20508095 0.83 WNT3A (0.52) WNT3A
SCHEMBL20507976 0.82 WNT3A (0.51) WNT3A
SCHEMBL20508144 0.82 WNT3A (0.52) WNT3A
SCHEMBL20508205 0.81 PPARG (0.54) WNT3A
SCHEMBL20508020 0.79 WNT3A (0.49) WNT3ANPC1RAB9A
SCHEMBL20507940 0.79 WNT3A (0.57) WNT3ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 — — EP claimed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 — — US claimed
EP-3388428-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Company (CN) 2018-10-17 — — EP claimed
US-20180271846-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2018-09-27 — — US claimed
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 — — EP disclosed
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 — — EP disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 — — US disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 — — US disclosed
EP-3388428-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Company (CN) 2018-10-17 — — EP disclosed
US-20180271846-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2018-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180271846-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR WNT1, WNT3, WNT3A WNT3A 3/4885NPC1 3356/4885RAB9A 810/4885
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor WNT1, WNT3, WNT3A WNT3A 3/4885NPC1 3617/4885RAB9A 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback